This infographic explores how healthy the orphan drug pipeline really is as these drugs are set to generate billions worldwide by 2032.
Despite policy and pricing turmoil across the pharmaceutical industry, orphan drug sales continue to rise steadily and remain stable for most of the market’s leading companies. In fact, important policy wins are supporting strong sales trajectories. But orphan drug developers must navigate carefully as they confront a temperamental FDA and compete for attention with blockbusters in obesity and other common disease areas.
This infographic explores how healthy the orphan drug pipeline really is as these drugs are set to generate billions worldwide in the next six years. And there remains untapped growth potential for the unmet need of rare diseases. Highlights include:
- A look at eight top selling orphan drugs set to generate billions in 2032 projected sales.
- Forecasts for how orphan drugs will remain stable for most of the orphan drug market’s leading companies.
- How pipeline leaders are subject to all the risks — including regulatory risk — inherent in orphan drug development.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Evaluate
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Evaluate
